CLRB
$3.30
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States.
Intraday
Recent News
Cellectar Biosciences, Inc. Q4 2025 Earnings Call Summary
Moby summary of Cellectar Biosciences, Inc.'s Q4 2025 earnings call
Cellectar (CLRB) Q4 2025 Earnings Call Transcript
Need a quote from a Motley Fool analyst? Jim Caruso, President and CEO, who will provide an overview of the company's progress before turning the call over to Chad Kolean, CFO, for a financial review of the quarter and the year. Following this, Jarrod Longcor, Chief Operating Officer, will give an update on the company's progress and plans for its promising clinical development pipeline of radiopharmaceuticals.
Cellectar Biosciences Inc (CLRB) Q3 2025 Earnings Call Highlights: Strategic Advances and ...
Cellectar Biosciences Inc (CLRB) progresses with regulatory approvals and partnerships, while navigating financial hurdles for future growth.
Cellectar Says FDA Grants Rare Pediatric Drug Designation for Iopofosine in High-Grade Glioma
Cellectar Biosciences (CLRB) said Monday that the US Food and Drug Administration has granted its in
All You Need to Know About Cellectar Biosciences (CLRB) Rating Upgrade to Buy
Cellectar Biosciences (CLRB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.